[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

ADMA Biologics Reports Tuesday but the Channel Stuffing Allegations Haven't Gone Away

ADMA Biologics reports first-quarter 2026 earnings after market close on May 6, 2026, with the stock trading at $10.25—down sharply from recent highs and sitting well below all major moving averages. The central question: can this specialty biopharmaceutical company demonstrate continued momentum in its plasma-derived immunoglobulin franchise amid a deteriorating technical backdrop and increasingly cautious analyst sentiment?

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients. Its primary commercial products include ASCENIV and BIVIGAM—FDA-approved immunoglobulin therapies for primary humoral immunodeficiency—along with NABI-HB for hepatitis B prevention.

Fundamentals

See More
  • Market Capitalization, $K 2,455,420
  • Shares Outstanding, K 238,159
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 192 M
  • EBITDA $ 200 M
  • 60-Month Beta 0.83
  • Price/Sales 4.91
  • Price/Cash Flow 16.08
  • Price/Book 5.24

Options Overview Details

View History
  • Implied Volatility 90.06% (-0.55%)
  • Historical Volatility 94.57%
  • IV Percentile 86%
  • IV Rank 46.78%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 10) 1.45 (14.10%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 1,534
  • Volume Avg (30-Day) 3,383
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 136,730
  • Open Int (30-Day) 146,095
  • Expected Range 8.81 to 11.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.14
  • Growth Rate Est. (year over year) +713,471.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.09 +12.76%
on 04/07/26
11.42 -10.25%
on 04/24/26
+1.06 (+11.53%)
since 04/02/26
3-Month
7.21 +42.16%
on 03/26/26
17.16 -40.27%
on 03/02/26
-5.69 (-35.70%)
since 02/05/26
52-Week
7.21 +42.16%
on 03/26/26
23.98 -57.26%
on 05/07/25
-13.46 (-56.77%)
since 05/05/25

Most Recent Stories

More News
ADMA Biologics Reports Tuesday but the Channel Stuffing Allegations Haven't Gone Away

Barchart Research What to Expect from ADMA Earnings ADMA Generated May 5, 2026 Current Price $10.25 Consensus Rating Moderate Buy Average Move 14.00% ADMA Biologics Reports Tuesday but the Channel Stuffing...

ADMA : 10.25 (-0.58%)
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 10.25 (-0.58%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , May 1, 2026 /PRNewswire/ --

ADMA : 10.25 (-0.58%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised...

ADMA : 10.25 (-0.58%)
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 10.25 (-0.58%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , April 25, 2026 /PRNewswire/ --

ADMA : 10.25 (-0.58%)
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating

ADMA Investors with Losses Encouraged to Contact the Firm

ADMA : 10.25 (-0.58%)
Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:  ...

ADMA : 10.25 (-0.58%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , April 20, 2026 /PRNewswire/ --

ADMA : 10.25 (-0.58%)
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:  ADMA ) investors concerning the Company’s possible...

ADMA : 10.25 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 11.03
2nd Resistance Point 10.80
1st Resistance Point 10.52
Last Price 10.25
1st Support Level 10.01
2nd Support Level 9.78
3rd Support Level 9.50

See More

52-Week High 23.98
Fibonacci 61.8% 17.57
Fibonacci 50% 15.60
Fibonacci 38.2% 13.62
Last Price 10.25
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.